Join
Live feed
·
PRReleasevia Quantisnow
Crinetics Pharmaceuticals Inc. logo

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

ByQuantisnow·Wall Street's wire, on your screen.
CRNX· Crinetics Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRNX (Crinetics Pharmaceuticals Inc.) and more on Quantisnow.